fluorouracil has been researched along with Dysphagia in 62 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malignant esophageal stenosis is a common and severe complication of advanced esophageal cancer that can be a serious problem in the continuation of chemotherapy and other anticancer treatments." | 5.91 | Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis. ( Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Okamoto, K; Saito, H; Shimada, M; Tsuji, T; Yamaguchi, T, 2023) |
| "These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study, but at the cost of less morbidity." | 5.08 | Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. ( Ackland, SP; Burmeister, BH; Denham, JW; Devitt, P; Gill, PG; Hamilton, CS; Jamieson, GG; Lamb, DS; O'Brien, M; Yeoh, E, 1995) |
| " Here, we report the case of a successfully treated patient with thoracic esophageal cancer who had esophageal perforation during docetaxel, cisplatin, and 5-fluorouracil chemotherapy." | 3.91 | Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy. ( Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M, 2019) |
| "Patients with locally advanced (cT3 or N+) esophageal and esophagogastric junction adenocarcinoma undergoing neoadjuvant TCF [Taxotere, cisplatin 5-fluorouracil (5-FU)], ECF (epirubicin, cisplatin, 5-FU), or FLOT (docetaxel, oxaliplatin, leucovorin, and 5-FU) at the McGill University Health Center from March 2007 to September 2012 were identified from a prospective database." | 3.81 | Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? ( Alcindor, T; Asselah, J; Cools-Lartigue, J; Eckert, E; Ferri, LE; Jones, D; Rousseau, M; Spicer, J; Vanhuyse, M; Zourikian, T, 2015) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| " We report on a clinical deterioration, yet near-complete pathological and radiological response to a combination of cisplatin and fluorouracil in a patient with locally-advanced gastric adenocarcinoma." | 3.69 | Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. ( Crellin, A; Guillou, PJ; Hassan, S; Macadam, R; Reynolds, JV; Sadek, SA; Somers, SS; Windsor, AC, 1995) |
| " 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma." | 3.64 | PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER. ( HART, GD, 1964) |
| "Acute Grade 3 (G3) dysphagia was higher in DL2 (87% DL2 vs." | 2.77 | Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. ( A'hern, R; Barbachano, Y; Bhide, SA; Bidmead, AM; Clark, C; Guerrero-Urbano, MT; Harrington, KJ; Hickey, J; Miah, AB; Newbold, KL; Nicol, R; Nutting, CM; St Rose, S; Tanay, M, 2012) |
| "The peak prevalence of grade 3 dysphagia was higher and the recovery was slower in patients with lower OTT (median 38 days vs." | 2.75 | Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. ( Bhide, SA; Fowler, J; Gulliford, S; Harrington, KJ; Newbold, K; Nutting, CM; Rosenfelder, N, 2010) |
| "The median dysphagia free time was 9." | 2.71 | A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. ( Glynne-Jones, R; Goodchild, K; Harney, J; Hoskin, PJ; Phillips, H; Saunders, MI, 2003) |
| "Dysphagia was measured at the beginning and completion of treatment and at monthly intervals until death, using a modified DeMeester (4-point) score." | 2.71 | Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. ( Beller, E; Bessell, JR; Burmeister, BH; Burmeister, E; Doyle, L; Gotley, DC; Harvey, JA; Martin, I; Smithers, BM; Thomas, J; Thomson, DB; Walpole, ET, 2004) |
| "Relief of dysphagia and other symptoms were monitored, together with body weight changes." | 2.70 | Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. ( Artru, P; Baujat, B; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Maindrault, F; Taïeb, J; Tournigand, C, 2002) |
| "The outlook for patients with oesophageal cancer undergoing surgical resection with curative intent is poor." | 2.70 | Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. ( , 2002) |
| "For these patients, the median dysphagia-free interval from time of onset of improvement was 11 weeks (range 1-131 weeks) and 11 (73%) remained dysphagia-free until death." | 2.69 | A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. ( Hayter, CR; Huff-Winters, C; Paszat, L; Schulze, K; Shelley, WE; Youssef, YM, 2000) |
| "Significant improvement in dysphagia was recorded in 76% patients with complete response in 47 cases ranging from 6 to 27 months." | 2.67 | The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study. ( Desai, PB; Deshpande, R; Dinshaw, KA; Malliat, MK; Pendse, AM; Sharma, V; Telang, CS; Vege, SS, 1991) |
| "Malignant esophageal stenosis is a common and severe complication of advanced esophageal cancer that can be a serious problem in the continuation of chemotherapy and other anticancer treatments." | 1.91 | Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis. ( Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Okamoto, K; Saito, H; Shimada, M; Tsuji, T; Yamaguchi, T, 2023) |
| "Currently, no disease recurrence, dysphagia, or respiratory symptoms have been reported at 13 months after initiating chemoradiotherapy." | 1.56 | Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report. ( Fujii, K; Mizowaki, T; Sakanaka, K, 2020) |
| "She was diagnosed with esophageal cancer (cT3N2M0, stage III)." | 1.56 | A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. ( Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N, 2020) |
| "Dysphagia is a major symptom of esophageal cancer (EC) that significantly affects patient quality of life; however, little is known regarding its clinical impact on the treatment course in patients with EC." | 1.51 | Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. ( Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M, 2019) |
| "The overall rate of improvement in the dysphagia score was 60%." | 1.48 | Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia. ( Karasawa, K; Kawamoto, T; Nihei, K; Sasai, K, 2018) |
| "Dysphagia is the main symptom of cancer of the esophagus and gastroesophageal junction and causing nutritional problems and weight loss, often counteracted by insertion of self-expandable metal stents or nutrition via an enteral route." | 1.43 | Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction. ( Ericson, J; Friesland, S; Kumagai, K; Lindblad, M; Lundell, L; Nilsson, M; Rouvelas, I; Sunde, B; Tsai, JA; Wang, N, 2016) |
| "After 4 weeks, dysphagia scores improved by at least 1 point in 67% of patients in group 1 versus 93% in group 2 (p=0." | 1.40 | Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. ( Archambeaud, I; Landi, B; Lepère, C; Lièvre, A; Mitry, E; Rougier, P; Touchefeu, Y, 2014) |
| " SERMS are a safe and effective intervention in dysphagic patients undergoing neoadjuvant chemotherapy for esophageal cancer." | 1.38 | Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. ( Gilani, SQ; Jain, PK; Pellen, MG; Razack, A; Sabri, S, 2012) |
| "Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications." | 1.37 | Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011) |
| "Obesity is a risk factor for the development of esophageal malignancy." | 1.37 | Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity. ( Mathew, J; Odell, JA; Stauffer, JA, 2011) |
| "Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy between December 1998 and March 2006 were reviewed retrospectively." | 1.36 | Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers. ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2010) |
| "Severe dysphagia (Grade 3-4) was observed in 22 patients (47%) as an acute toxic event." | 1.35 | Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers. ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2009) |
| " The plasma 5-FU level was measured, and adverse events appearing after administration were monitored." | 1.33 | [Pharmacokinetics and adverse event of TS-1 administered through gastrostomy]. ( Hasegawa, M; Hirano, K; Nakamura, K, 2005) |
| "Grade 3 dysphagia-esophageal related to radiation was observed in 3 patients (9." | 1.33 | [Hyperfractionated radiotherapy with concurrent chemotherapy for advanced esophageal cancer]. ( Asakura, H; Hosokawa, N; Kiuchi, T; Mitani, M; Ohkawa, M; Seo, H; Takashima, H; Togami, T; Yokoe, K, 2005) |
| "Rare reports of intestinal obstruction have been confined to the stiff plastic and stainless-steel stents." | 1.32 | A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). ( Ho, HS; Ong, HS, 2004) |
| "Dysphagia is the earliest and the most common symptom of malignant disease in the esophagus." | 1.29 | Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. ( Albertsson, M; Cwikiel, M; Cwikiel, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.45) | 18.7374 |
| 1990's | 6 (9.68) | 18.2507 |
| 2000's | 22 (35.48) | 29.6817 |
| 2010's | 26 (41.94) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Yamaguchi, T | 1 |
| Okamoto, K | 1 |
| Saito, H | 1 |
| Shimada, M | 1 |
| Tsuji, T | 1 |
| Moriyama, H | 1 |
| Kinoshita, J | 1 |
| Nakamura, K | 2 |
| Inaki, N | 1 |
| Hagi, T | 1 |
| Makino, T | 2 |
| Yamasaki, M | 2 |
| Tanaka, K | 2 |
| Nishida, N | 1 |
| Sakai, D | 1 |
| Motoori, M | 1 |
| Kimura, Y | 1 |
| Satoh, T | 1 |
| Mori, M | 2 |
| Doki, Y | 2 |
| Borg, D | 1 |
| Sundberg, J | 1 |
| Brun, E | 1 |
| Kjellén, E | 1 |
| Petersson, K | 1 |
| Hermansson, M | 1 |
| Johansson, J | 1 |
| Eberhard, J | 1 |
| Johnsson, A | 1 |
| Sakanaka, K | 1 |
| Fujii, K | 1 |
| Mizowaki, T | 1 |
| Vellayappan, BA | 1 |
| Soon, YY | 1 |
| Ku, GY | 1 |
| Leong, CN | 1 |
| Lu, JJ | 1 |
| Tey, JC | 1 |
| Francis, SR | 1 |
| Orton, A | 1 |
| Thorpe, C | 1 |
| Stoddard, G | 1 |
| Lloyd, S | 1 |
| Anker, CJ | 1 |
| Yu, FJ | 1 |
| Shih, HY | 1 |
| Wu, CY | 1 |
| Chuang, YS | 1 |
| Lee, JY | 1 |
| Li, HP | 1 |
| Fang, PT | 1 |
| Tsai, DL | 1 |
| Chou, SH | 1 |
| Wu, IC | 1 |
| Kawamoto, T | 1 |
| Nihei, K | 2 |
| Sasai, K | 1 |
| Karasawa, K | 1 |
| Kobayashi, T | 1 |
| Hayakawa, Y | 1 |
| Kobayashi, K | 1 |
| Sakamoto, N | 1 |
| Matsuoka, M | 1 |
| Nozaka, T | 1 |
| Misumi, Y | 1 |
| Matsumoto, T | 1 |
| Miura, N | 1 |
| Furumoto, Y | 1 |
| Asano, T | 1 |
| Horiuchi, T | 1 |
| Fujiki, K | 1 |
| Wong, S | 1 |
| Hennequin, C | 1 |
| Quero, L | 1 |
| Denaro, N | 1 |
| Russi, EG | 1 |
| Merlano, MC | 1 |
| Touchefeu, Y | 1 |
| Archambeaud, I | 1 |
| Landi, B | 1 |
| Lièvre, A | 1 |
| Lepère, C | 1 |
| Rougier, P | 1 |
| Mitry, E | 1 |
| Wopken, K | 1 |
| Bijl, HP | 1 |
| van der Schaaf, A | 1 |
| van der Laan, HP | 1 |
| Chouvalova, O | 1 |
| Steenbakkers, RJ | 1 |
| Doornaert, P | 1 |
| Slotman, BJ | 1 |
| Oosting, SF | 1 |
| Christianen, ME | 1 |
| van der Laan, BF | 1 |
| Roodenburg, JL | 1 |
| Leemans, CR | 1 |
| Verdonck-de Leeuw, IM | 1 |
| Langendijk, JA | 1 |
| Cools-Lartigue, J | 1 |
| Jones, D | 1 |
| Spicer, J | 1 |
| Zourikian, T | 1 |
| Rousseau, M | 1 |
| Eckert, E | 1 |
| Alcindor, T | 1 |
| Vanhuyse, M | 1 |
| Asselah, J | 1 |
| Ferri, LE | 1 |
| Sunde, B | 1 |
| Ericson, J | 1 |
| Kumagai, K | 1 |
| Lundell, L | 1 |
| Tsai, JA | 1 |
| Lindblad, M | 1 |
| Rouvelas, I | 1 |
| Friesland, S | 1 |
| Wang, N | 1 |
| Nilsson, M | 1 |
| Otter, S | 1 |
| Schick, U | 1 |
| Gulliford, S | 2 |
| Lal, P | 1 |
| Franceschini, D | 1 |
| Newbold, K | 2 |
| Nutting, C | 1 |
| Harrington, K | 1 |
| Bhide, S | 1 |
| Nakata, Y | 1 |
| Ijichi, K | 1 |
| Hanai, N | 1 |
| Nishikawa, D | 1 |
| Suzuki, H | 1 |
| Hirakawa, H | 1 |
| Kodaira, T | 1 |
| Fujimoto, Y | 1 |
| Fujii, T | 1 |
| Miyazaki, T | 1 |
| Shimizu, T | 1 |
| Hasegawa, Y | 1 |
| Sakaguchi, M | 1 |
| Maebayashi, T | 1 |
| Aizawa, T | 1 |
| Ishibashi, N | 1 |
| Saito, T | 1 |
| Nguyen, NP | 1 |
| Frank, C | 1 |
| Moltz, CC | 1 |
| Vos, P | 1 |
| Smith, HJ | 1 |
| Nguyen, PD | 1 |
| Martinez, T | 1 |
| Karlsson, U | 1 |
| Dutta, S | 1 |
| Lemanski, C | 1 |
| Nguyen, LM | 1 |
| Sallah, S | 1 |
| Koiwai, K | 2 |
| Shikama, N | 2 |
| Sasaki, S | 2 |
| Shinoda, A | 2 |
| Kadoya, M | 2 |
| Chay, WY | 1 |
| Chew, L | 1 |
| Yeoh, TT | 1 |
| Tan, MH | 1 |
| Bhide, SA | 2 |
| Fowler, J | 1 |
| Rosenfelder, N | 1 |
| Harrington, KJ | 2 |
| Nutting, CM | 2 |
| Thukral, A | 1 |
| Metz, J | 1 |
| Hwang, WT | 1 |
| O'Dwyer, P | 1 |
| Plastaras, J | 1 |
| Both, S | 1 |
| Bar-Ad, V | 1 |
| Ad, VB | 1 |
| Stauffer, JA | 1 |
| Mathew, J | 1 |
| Odell, JA | 1 |
| Miah, AB | 1 |
| Guerrero-Urbano, MT | 1 |
| Clark, C | 1 |
| Bidmead, AM | 1 |
| St Rose, S | 1 |
| Barbachano, Y | 1 |
| A'hern, R | 1 |
| Tanay, M | 1 |
| Hickey, J | 1 |
| Nicol, R | 1 |
| Newbold, KL | 1 |
| Pellen, MG | 1 |
| Sabri, S | 1 |
| Razack, A | 1 |
| Gilani, SQ | 1 |
| Jain, PK | 1 |
| Ikeda, E | 1 |
| Kojima, T | 1 |
| Kaneko, K | 1 |
| Minashi, K | 1 |
| Onozawa, M | 1 |
| Fuse, N | 1 |
| Yano, T | 1 |
| Yoshino, T | 1 |
| Tahara, M | 1 |
| Doi, T | 1 |
| Ohtsu, A | 1 |
| Kofoed, SC | 1 |
| Lundsgaard, M | 1 |
| Ellemann, AC | 1 |
| Svendsen, LB | 1 |
| Aguilar-Ponce, JL | 1 |
| Granados-García, M | 1 |
| Cruz López, JC | 1 |
| Maldonado-Magos, F | 1 |
| Alvarez-Avitia, MA | 1 |
| Arrieta, O | 1 |
| González-Ramírez, I | 1 |
| Lara-Cruz, G | 1 |
| Martinez-Juárez, I | 1 |
| Medina-Santillan, R | 1 |
| Castillo-Hernández, C | 1 |
| De la Garza-Salazar, J | 1 |
| Lucchetta, M | 1 |
| Lonardi, S | 1 |
| Bergamo, F | 1 |
| Alberti, P | 1 |
| Velasco, R | 1 |
| Argyriou, AA | 1 |
| Briani, C | 1 |
| Bruna, J | 1 |
| Cazzaniga, M | 1 |
| Cortinovis, D | 1 |
| Cavaletti, G | 1 |
| Kalofonos, HP | 1 |
| Beech, DJ | 1 |
| Madan, AK | 1 |
| Aliabadi-Wahle, S | 1 |
| Hays, AN | 1 |
| Long, WP | 1 |
| Harney, J | 1 |
| Goodchild, K | 1 |
| Phillips, H | 1 |
| Glynne-Jones, R | 1 |
| Hoskin, PJ | 1 |
| Saunders, MI | 1 |
| Jessner, W | 1 |
| Vogelsang, H | 1 |
| Püspök, A | 1 |
| Ferenci, P | 1 |
| Gangl, A | 1 |
| Novacek, G | 1 |
| Bodisch, A | 1 |
| Wenzl, E | 1 |
| Nahon, P | 1 |
| Artru, P | 2 |
| Tournigand, C | 2 |
| Louvet, C | 2 |
| Krulik, M | 2 |
| De Gramont, A | 2 |
| HART, GD | 1 |
| Ho, HS | 1 |
| Ong, HS | 1 |
| Patonay, P | 2 |
| Naszály, A | 2 |
| Mayer, A | 2 |
| Harvey, JA | 1 |
| Bessell, JR | 1 |
| Beller, E | 1 |
| Thomas, J | 1 |
| Gotley, DC | 1 |
| Burmeister, BH | 2 |
| Walpole, ET | 1 |
| Thomson, DB | 1 |
| Martin, I | 1 |
| Doyle, L | 1 |
| Burmeister, E | 1 |
| Smithers, BM | 1 |
| Chan, L | 1 |
| Yeo, W | 1 |
| Leung, SF | 2 |
| Griffith, J | 1 |
| Ng, EK | 2 |
| Chan, AT | 1 |
| Hirano, K | 1 |
| Hasegawa, M | 1 |
| Asakura, H | 1 |
| Takashima, H | 1 |
| Yokoe, K | 1 |
| Togami, T | 1 |
| Mitani, M | 1 |
| Kiuchi, T | 1 |
| Hosokawa, N | 1 |
| Seo, H | 1 |
| Ohkawa, M | 1 |
| Minsky, BD | 1 |
| Demizu, Y | 1 |
| Sasaki, R | 1 |
| Soejima, T | 1 |
| Maruta, T | 1 |
| Okamoto, Y | 1 |
| Yamada, K | 1 |
| Yoden, E | 1 |
| Ejima, Y | 1 |
| Ota, Y | 1 |
| Ishida, H | 1 |
| Nibu, K | 1 |
| Sugimura, K | 1 |
| Allen, AM | 1 |
| Elshaikh, M | 1 |
| Worden, FP | 1 |
| Bradford, CR | 1 |
| Teknos, TN | 1 |
| Chepeha, DB | 1 |
| Tsien, C | 1 |
| Dawson, LA | 1 |
| Urba, S | 1 |
| Wolf, GT | 1 |
| Normolle, D | 1 |
| Eisbruch, A | 1 |
| Wong, SK | 1 |
| Chiu, PW | 1 |
| Cheung, KY | 1 |
| Chan, AC | 1 |
| Au-Yeung, AC | 1 |
| Griffith, JF | 1 |
| Chung, SS | 1 |
| Denham, JW | 1 |
| O'Brien, M | 1 |
| Jamieson, GG | 1 |
| Gill, PG | 1 |
| Devitt, P | 1 |
| Yeoh, E | 1 |
| Hamilton, CS | 1 |
| Ackland, SP | 1 |
| Lamb, DS | 1 |
| Cwikiel, M | 1 |
| Cwikiel, W | 1 |
| Albertsson, M | 1 |
| Windsor, AC | 1 |
| Somers, SS | 1 |
| Crellin, A | 1 |
| Hassan, S | 1 |
| Macadam, R | 1 |
| Sadek, SA | 1 |
| Guillou, PJ | 1 |
| Reynolds, JV | 1 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| García Girón, C | 1 |
| Espinosa, E | 1 |
| Vicent, JM | 1 |
| Gómez Navarro, J | 1 |
| Berrocal, A | 1 |
| Ordóñez, A | 1 |
| Vilches, Y | 1 |
| de Castro, J | 1 |
| Díaz, J | 1 |
| Stuschke, M | 1 |
| Stahl, M | 1 |
| Wilke, H | 1 |
| Walz, M | 1 |
| Oldenburg, A | 1 |
| Stüben, G | 1 |
| Seeber, S | 1 |
| Sack, H | 1 |
| Hayter, CR | 1 |
| Huff-Winters, C | 1 |
| Paszat, L | 1 |
| Youssef, YM | 1 |
| Shelley, WE | 1 |
| Schulze, K | 1 |
| Seitz, JF | 1 |
| Duffaud, F | 1 |
| Dahan, L | 1 |
| Ries, P | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Taïeb, J | 1 |
| Baujat, B | 1 |
| Mabro, M | 1 |
| Carola, E | 1 |
| Maindrault, F | 1 |
| Prostman, TJ | 1 |
| Schifter, M | 1 |
| Barrett, AP | 1 |
| Dinshaw, KA | 1 |
| Sharma, V | 1 |
| Pendse, AM | 1 |
| Telang, CS | 1 |
| Vege, SS | 1 |
| Malliat, MK | 1 |
| Deshpande, R | 1 |
| Desai, PB | 1 |
| Shaw, HJ | 1 |
| Holyoke, ED | 1 |
| Nemoto, T | 1 |
| Dao, TL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy[NCT03035071] | 26 participants (Actual) | Interventional | 2010-05-01 | Completed | |||
| A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123] | Phase 3 | 301 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fluorouracil and Dysphagia
| Article | Year |
|---|---|
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
Topics: Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deglut | 2017 |
[Brachytherapy for oesophageal cancer].
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Clinical Trials, Phase II as Topi | 2013 |
Primary combined-modality therapy for esophageal cancer.
Topics: Algorithms; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; | 2006 |
Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Carcinoma, | 1976 |
14 trials available for fluorouracil and Dysphagia
| Article | Year |
|---|---|
Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2020 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2012 |
A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Deglutitio | 2004 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
[Simultaneous radiochemotherapy and endoluminal HDR brachytherapy in esophageal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 2007 |
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aust | 1995 |
Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2000 |
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Combined Modality Therapy; Deglutition Disorders; Esoph | 1991 |
44 other studies available for fluorouracil and Dysphagia
| Article | Year |
|---|---|
Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis.
Topics: Cisplatin; Constriction, Pathologic; Deglutition Disorders; Docetaxel; Esophageal Stenosis; Fluorour | 2023 |
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2019 |
Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Ci | 2020 |
Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutiti | 2018 |
Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2019 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemor | 2020 |
Strategies for non-resectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2015 |
Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adj | 2016 |
Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Computer Graphics; De | 2015 |
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutition Diso | 2017 |
Analysis of factors influencing aspiration risk following chemoradiation for oropharyngeal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Barium Sulfat | 2009 |
Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women.
Topics: Adult; Aged; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deglutition | 2010 |
Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Squa | 2010 |
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2011 |
Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bariatric Surgery; Deglutition | 2011 |
Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; | 2012 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabi | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2012 |
Synchronous occurrence of glioblastoma multiforme and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplat | 2003 |
Plummer-Vinson syndrome associated with celiac disease and complicated by postcricoid carcinoma and carcinoma of the tongue.
Topics: Anemia, Iron-Deficiency; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Celiac Diseas | 2003 |
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2003 |
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms | 1964 |
A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex).
Topics: Adenocarcinoma; Aged; Alloys; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2004 |
[The radiochemotherapy of the oesophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Degl | 2004 |
Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Degluti | 2005 |
[Pharmacokinetics and adverse event of TS-1 administered through gastrostomy].
Topics: Deglutition Disorders; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gas Chromatogr | 2005 |
[Hyperfractionated radiotherapy with concurrent chemotherapy for advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deglutit | 2005 |
Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2006 |
Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Co | 2008 |
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1996 |
Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell | 2000 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
Multiple cranial nerve involvement leading to diagnosis of nasopharyngeal carcinoma: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cranial Nerves; Deglutition Disorders; Fl | 1992 |
Value of cytotoxic infusion in dyspnoea and dysphagia due to cancer.
Topics: Antineoplastic Agents; Cyclophosphamide; Deglutition Disorders; Dyspnea; Esophageal Neoplasms; Fluor | 1973 |
Esophageal metastases and dysphagia in patients with carcinoma of the breast.
Topics: Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Deglutition Disorders; Dilatation; E | 1969 |